101
|
Abstract
INTRODUCTION Cognitive disorders are common in patients with epilepsy. Their aetiology is multifactorial, being affected by the type and location of the epileptogenic lesion, epileptic syndrome, type of seizures, age of onset, frequency and severity. Timely diagnosis and treatment can help to reduce their impact on the patient's quality of life. RESULTS The most significant cognitive deficits are associated with focal epilepsy, although some, usually mild, neuropsychological disorders can be found in idiopathic generalized epilepsy. The use of antiepileptic drugs (AEDs) can cause additional neuropsychological disorders that are of particular concern in learning-age children and elderly patients with cognitive disorders before the start of treatment. Recent studies have raised the concern that the use of some AEDs during pregnancy may cause cognitive disorders in the child exposed to them in utero. Cognitive disorders can also present as a complication of surgery for refractory epilepsy. Some risk factors for significant memory loss after surgery for temporal lobe epilepsy have been described. They include intervention in the dominant hemisphere, good preoperative function and poor functional reserve in the contralateral hippocampus. CONCLUSIONS The heterogeneity of different types of epilepsy makes case-control studies difficult; however, thanks to the growing interest in the neuropsychological deficits associated with epilepsy, we now know some factors that could lead to the appearance of these disorders and their prognosis. Special care must be taken to detect cognitive side effects associated with AEDs, which seem to be more common with classic than with new AEDs, and in those patients receiving polytherapy. Neuropsychological assessment should be routinely performed before epilepsy surgery to predict possible postsurgical cognitive deficits.
Collapse
|
102
|
Labiner DM, Ettinger AB, Fakhoury TA, Chung SS, Shneker B, Tatum IV WO, Mitchell Miller J, Vuong A, Hammer AE, Messenheimer JA. Effects of lamotrigine compared with levetiracetam on anger, hostility, and total mood in patients with partial epilepsy. Epilepsia 2009; 50:434-42. [DOI: 10.1111/j.1528-1167.2008.01792.x] [Citation(s) in RCA: 58] [Impact Index Per Article: 3.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
103
|
Patient-reported cognitive side effects of antiepileptic drugs: predictors and comparison of all commonly used antiepileptic drugs. Epilepsy Behav 2009; 14:202-9. [PMID: 19010446 DOI: 10.1016/j.yebeh.2008.10.017] [Citation(s) in RCA: 93] [Impact Index Per Article: 6.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/04/2008] [Revised: 10/14/2008] [Accepted: 10/15/2008] [Indexed: 11/23/2022]
Abstract
Subjective cognitive side effects (CSEs) are common in patients taking antiepileptic drugs (AEDs). The objective of this study was to predict which patients are at risk for CSEs, and compare the CSE profiles of all commonly used AEDs. In this nonrandomized retrospective study, medical records of 1694 adult outpatients with epilepsy seen at our center over a 5-year period who had taken one or more AEDs were examined. Non-AED predictors of CSEs were investigated, and rates of AED-related CSEs were compared in 1189 patients (546 on monotherapy) newly started on an AED at our center. The average rate of AED-related intolerable CSEs (leading to dosage change or discontinuation) was 12.8%. On multivariate analysis, no significant non-AED predictors of CSEs were found. Significantly more intolerable CSEs were attributed to topiramate (21.5% of 130 patients) than to most other AEDs, including carbamazepine (9.9%), gabapentin (7.3%), levetiracetam (10.4%), lamotrigine (8.9%), oxcarbazepine (11.6%), and valproate (8.3%). CSE rates with zonisamide (14.9%) were significantly higher than those for gabapentin and lamotrigine. After exclusion of CSEs during the first 8 weeks of therapy, rates of CSEs were lower, but relative differences remained unchanged. In monotherapy, significantly more intolerable CSEs occurred with topiramate (11.1% of 18 patients) than with carbamazepine or valproate, and both phenytoin and zonisamide were associated with more CSEs than valproate. From this study, it can be concluded that intolerable patient-reported CSEs are most common with topiramate, followed by zonisamide, phenytoin, and oxcarbazepine. They are least likely to be reported with gabapentin, valproate, lamotrigine, carbamazepine, and levetiracetam.
Collapse
|
104
|
The impact of side effects on long-term retention in three new antiepileptic drugs. Seizure 2008; 18:327-31. [PMID: 19110447 DOI: 10.1016/j.seizure.2008.11.006] [Citation(s) in RCA: 89] [Impact Index Per Article: 5.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/30/2008] [Revised: 11/17/2008] [Accepted: 11/20/2008] [Indexed: 01/11/2023] Open
Abstract
OBJECTIVE To determine long-term retention, percentage of patients withdrawing because of adverse events, percentage of patients achieving seizure freedom, safety profile of the new anti-epileptic drugs lamotrigine, levetiracetam and topiramate. METHODS All patients treated with lamotrigine, levetiracetam or topiramate in the Epilepsy Centre were identified. Each drug was analyzed from introduction of the drug in the Netherlands up to a final assessment point 2 years later. RESULTS Data from 1066 patients were included: 336 for lamotrigine, 301 for levetiracetam, 429 for topiramate. Two-year retention rates were 69.2% (lamotrigine), 45.8% (levetiracetam), 38.3% (topiramate); (LTG vs. LEV at p<0.001; LTG vs. TPM at p<0.001; LEV vs. TPM at p=0.005). Seizure freedom rates were lowest for lamotrigine and highest for levetiracetam. Adverse events played a role in drug discontinuation in 154/429 patients (35.9%) on topiramate, 52/336 patients (15.5%) on lamotrigine (p<0.001), 68/301 patients (22.5%) on levetiracetam (p<0.001). Mood and general CNS-effects are common in patients on lamotrigine and levetiracetam, and neurocognitive side effects are most prevalent in patients on topiramate. A positive effect on cognition is frequently noted in patients on lamotrigine. CONCLUSION A drug that is only modestly efficacious but has a favourable safety profile may look better than a drug that is more efficacious but produces clinically meaningful adverse events. Therefore, a drug's retention rate is mainly determined by its side effect profile. As a consequence, retention rate was highest for lamotrigine and lowest for topiramate. Intermediate retention rates were seen with levetiracetam use.
Collapse
|
105
|
Novy J, Hubschmid M, Michel P, Rossetti AO. Impending status epilepticus and anxiety in a pregnant woman treated with levetiracetam. Epilepsy Behav 2008; 13:564-6. [PMID: 18589001 DOI: 10.1016/j.yebeh.2008.06.004] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/23/2008] [Revised: 06/06/2008] [Accepted: 06/06/2008] [Indexed: 11/16/2022]
Abstract
Levetiracetam (LEV) has been considered to undergo no significant change in bioavailability during pregnancy; however, it was recently demonstrated to display modifications leading to a drop in its serum level. We describe a patient who displayed impending status epilepticus following a fall in her LEV level during the first trimester. The oral LEV dosage was increased, and phenytoin and benzodiazepines were transiently prescribed. She experienced severe anxiety and an unbearable fear over the deleterious consequences for her baby despite repeated, reassuring explanations. Her anxiety was so strong that she aborted electively shortly after leaving the hospital. This observation emphasizes the need for LEV level monitoring during pregnancy to prevent unexpected seizure relapses. The rapid increase in levetiracetam dosage in parallel with the loss of seizure control is suspected of facilitating the induction of significant psychiatric changes.
Collapse
Affiliation(s)
- Jan Novy
- Department of Neurology, Centre Hospitalier Universitaire Vaudois and University of Lausanne, Lausanne, Switzerland
| | | | | | | |
Collapse
|
106
|
Abstract
Epilepsy is a common condition that affects up to 1% of the population. Patients with epilepsy are particularly sensitive to the adverse effects of sleep disruption. Failure to recognize and treat sleep disturbances can lead to worsening of attention, cognitive functioning, and quality of life, and can increase seizures. Anticonvulsant agents have the potential to either improve or worsen sleep and sleep disorders in patients with epilepsy. Therefore, awareness of the implications of sleep disorders and anticonvulsants is critical for the optimal care of patients with epilepsy.
Collapse
|
107
|
Alterations in the contents of consciousness in partial epileptic seizures. Epilepsy Behav 2008; 13:366-71. [PMID: 18522873 DOI: 10.1016/j.yebeh.2008.04.014] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/03/2008] [Revised: 04/15/2008] [Accepted: 04/18/2008] [Indexed: 11/20/2022]
Abstract
Epilepsy research suffers from a deficiency of systematic studies concerning the phenomenology of the contents of consciousness during seizures, partially because of the lack of suitable research methods. The Phenomenology of Consciousness Inventory (PCI), a standardized, valid, and reliable questionnaire, was used here to study which dimensions of the contents of consciousness are distorted during partial epileptic seizures compared with baseline. Further, the similarity of the altered pattern of subjective experiences across recurring seizures was also explored. Our results indicate that patients with epilepsy report alterations on most dimensions of the contents of consciousness in conjunction with seizures, but individual seizure experiences remain similar from one seizure to another. The PCI was found suitable for the assessment of subjective experiences during epileptic seizures and could be a valuable tool in providing new information about phenomenal consciousness in epilepsy in both the research and clinical settings.
Collapse
|
108
|
Intravenous levetiracetam: treatment experience with the first 50 critically ill patients. Epilepsy Behav 2008; 12:477-80. [PMID: 18291724 DOI: 10.1016/j.yebeh.2008.01.004] [Citation(s) in RCA: 84] [Impact Index Per Article: 5.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/21/2007] [Revised: 01/10/2008] [Accepted: 01/11/2008] [Indexed: 10/22/2022]
Abstract
Levetiracetam (LEV) is a broad-spectrum antiepileptic drug with no known interactions and a favorable profile of adverse events. These properties make it a good candidate for use in critically ill patients. An intravenous formulation of LEV was recently approved. The present study retrospectively assesses the safety and efficacy of LEV in the first 50 critically ill patients treated with intravenous LEV. Indications for use were seizure prophylaxis, acute symptomatic seizures, and all forms of status epilepticus. There were no major adverse effects, although less prominent changes may have been masked by the already severely compromised condition of these patients. Two patients (4%) had transiently lowered platelet counts (55,000 and 82,000, respectively). Efficacy, defined as cessation of seizure activity or prevention of its recurrence, was observed in 41 of 50 patients (82%). Antiepileptic treatment of critically ill patients with LEV seems to be effective and safe according to the data for this small cohort, but this observation warrants further prospective investigation in a larger number of patients.
Collapse
|
109
|
Shin HK, Lee Y, Lee JY, Choi W, Eun SH, Eun BL, Hong YS, Lee JW. Efficacy and safety of oxcarbazepine in epileptic children. KOREAN JOURNAL OF PEDIATRICS 2008. [DOI: 10.3345/kjp.2008.51.2.162] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
Affiliation(s)
| | - Yoon Lee
- Korea University College of Medicine, Seoul, Korea
| | - Jee-Yeon Lee
- Department of Pediatrics, Kwangmyung-Sungae Hospital, Kwangmyung, Korea
| | - Wooksun Choi
- Korea University College of Medicine, Seoul, Korea
| | - So-Hee Eun
- Korea University College of Medicine, Seoul, Korea
| | - Baik-Lin Eun
- Korea University College of Medicine, Seoul, Korea
| | | | - Joo Won Lee
- Korea University College of Medicine, Seoul, Korea
| |
Collapse
|
110
|
Crooks CY, Zumsteg JM, Bell KR. Traumatic Brain Injury: A Review of Practice Management and Recent Advances. Phys Med Rehabil Clin N Am 2007; 18:681-710, vi. [DOI: 10.1016/j.pmr.2007.06.005] [Citation(s) in RCA: 36] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
111
|
Neuropsychological and Behavioral Effects of Antiepilepsy Drugs. Neuropsychol Rev 2007; 17:413-25. [DOI: 10.1007/s11065-007-9043-9] [Citation(s) in RCA: 139] [Impact Index Per Article: 8.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/31/2007] [Accepted: 09/27/2007] [Indexed: 11/27/2022]
|
112
|
Current awareness: Pharmacoepidemiology and drug safety. Pharmacoepidemiol Drug Saf 2007. [DOI: 10.1002/pds.1383] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022]
|
113
|
De Smedt T, Raedt R, Vonck K, Boon P. Levetiracetam: part II, the clinical profile of a novel anticonvulsant drug. CNS DRUG REVIEWS 2007; 13:57-78. [PMID: 17461890 PMCID: PMC6494152 DOI: 10.1111/j.1527-3458.2007.00005.x] [Citation(s) in RCA: 84] [Impact Index Per Article: 4.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Abstract
The objective of this article was to review and summarize the available reports on the profile of the novel anticonvulsant drug levetiracetam (LEV) in a clinical setting. Therefore, a careful search was conducted in the MEDLINE database and combined with guidelines from regulatory agencies, proceedings of professional scientific meetings, and information provided by the manufacturers. This article is devoted to the clinical pharmacology and clinical trials of LEV investigating its efficacy and safety as add-on therapy or monotherapy for various seizure types. Finally, results from postmarketing surveillance of LEV are briefly discussed. In general, LEV is shown to be a safe, broad-spectrum anticonvulsant drug with highly beneficial pharmacokinetic properties, a favorable long-term retention rate, and a high responder rate, indicating that LEV is an efficient therapeutic option for the treatment of several types of epilepsy.
Collapse
Affiliation(s)
- Tim De Smedt
- Laboratory for Clinical and Experimental Neurophysiology - Reference Center for Refractory Epilepsy, University Hospital Ghent, Ghent, Belgium.
| | | | | | | |
Collapse
|
114
|
|
115
|
Bootsma HPR, Ricker L, Diepman L, Gehring J, Hulsman J, Lambrechts D, Leenen L, Majoie M, Schellekens A, de Krom M, Aldenkamp AP. Long-term effects of levetiracetam and topiramate in clinical practice: A head-to-head comparison. Seizure 2007; 17:19-26. [PMID: 17618131 DOI: 10.1016/j.seizure.2007.05.019] [Citation(s) in RCA: 41] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/31/2006] [Revised: 04/19/2007] [Accepted: 05/25/2007] [Indexed: 10/23/2022] Open
Abstract
OBJECTIVE Two of the most commonly prescribed new antiepileptic drugs as add-on therapy for patients with chronic refractory epilepsies are topiramate and levetiracetam. In regulatory trials, both drugs were characterized as very promising new antiepileptic drugs. However, results from these highly controlled short-term clinical trials cannot simply be extrapolated to everyday clinical practice, also because head-to-head comparisons are lacking. Therefore, results from long-term open label observational studies that compare two or more new AEDs are crucial to determine the long-term performance of competing new antiepileptic drugs in clinical practice. METHOD We analyzed all patients referred to a tertiary epilepsy centre who had been treated with topiramate from the introduction of the drug in spring 1993 up to a final assessment point mid-2002 and all patients who had been treated with LEV in the same centre from the introduction of the drug in early 2001 up to a final assessment point end-2003 using a medical information system. RESULTS Three hundred and one patients were included for levetiracetam and 429 patients for TPM. Retention rate after 1 year was 65.6% for LEV-treated patients and 51.7% for TPM-treated patients (p=0.0015). Similarly, retention rates for LEV were higher at the 24-month mark: 45.8% of LEV-treated patients and 38.3% of TPM-treated patients were still continuing treatment (p=0.0046). Adverse events led to drug discontinuation in 21.9% of TPM-treated patients compared to 6.0% of LEV-treated patients (p<0.001). The number of patients discontinuing treatment because of lack of efficacy was similar for both groups. Seizure freedom rates varied between 11.6 and 20.0% for TPM and between 11.1 and 14.3% for LEV per 6-months interval. Several important AED specific adverse events leading to drug discontinuation were identified, including neurocognitive side effects from TPM and mood disorders from LEV. CONCLUSION The retention rate for LEV is significantly higher than for TPM. LEV had a more favourable side effect profile than TPM with comparable efficacy. Patients on TPM discontinued treatment mainly because of neurocognitive side effects. In the treatment with LEV, the effects on mood must not be underestimated.
Collapse
Affiliation(s)
- H P R Bootsma
- Department of Neurology, Epilepsy Centre Kempenhaeghe, Heeze, The Netherlands.
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
116
|
Abstract
Levetiracetam is an antiepileptic drug approved for use as an adjunct agent in partial-onset seizures in adults and children aged > or = 4 years. It was also approved as adjunctive therapy in the treatment of adults and adolescents aged > or = 12 years with juvenile myoclonic epilepsy. A parenteral intravenous formulation has recently become available allowing for its use when oral administration is temporarily not feasible. Available literature has demonstrated and supported that levetiracetam has an acceptable safety profile and this review discusses the safety profile of levetiracetam, with attention to special populations. The most common adverse effects are somnolence, asthenia and dizziness, which usually appear early after initiation of levetiracetam therapy and generally resolve without medication withdrawal. The most serious adverse effects are behavioral in nature and are more common in children and in patients with a prior history of behavioral problems.
Collapse
Affiliation(s)
- Deepa Sirsi
- Weill Medical College of Cornell University, Division of Child Neurology, NY 10021, USA
| | | |
Collapse
|